Pharmafile Logo

Rob White

Biosimilars: Getting the flock to market

The biosimilars field is about to become very crowded. Here are some Life tips on how to stand out from the herd

Life Healthcare Communications

- PMLiVE

Merck & Co’s Remicade biosimilar undercuts its US rivals

Its version will be 35% cheaper than J&J's originator product

- PMLiVE

FDA panel backs Avastin and Herceptin biosimilars

A decision from the US regulator is expected in September

- PMLiVE

UK pharma launches legal challenge to NICE plans

Applies for judicial review of budget impact test

- PMLiVE

Standing out in a crowd

Celltrion Healthcare’s Ho-Ung Kim on pricing, market access and regulatory challenges for successfully developing biosimilars

Therapy Watch expands oncology and IBD portfolios

This month Therapy Watch expands its portfolio with the launch of several new trackers across numerous therapy areas including the launch of a new Chronic Myelogenous Leukaemia (CML) study in...

Research Partnership

- PMLiVE

Digital disruption in market access

Infinite possibilities

- PMLiVE

Facing the new wave of biosimilars

Don’t drown out the patient voice, says advocacy group

EULAR Annual European Congress of Rheumatology 2017

Join us at EULAR Congress 2017 in Madrid, 14-17 June

Research Partnership

- PMLiVE

Pfizer gets FDA panel recommendation for biosimilar EPO

Product could be the first direct competitor to Epogen and Procrit in the US

- PMLiVE

WHO pilots scheme to make biosimilars available to poorer countries

Plans to expand prequalification scheme to medicines such as Roche’s Rituxan and Herceptin

Research Partnership appoints Helen Parfitt as Director, Head of Therapy Watch

Helen Parfitt has joined Research Partnership as Head of Therapy Watch at the company’s global head office in London. Therapy Watch is a ‘real-time’ syndicated global market tracking tool that...

Research Partnership

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links